Skip Navigation


Journal of Intellectual Property Law & Practice Advance Access originally published online on February 28, 2008
Journal of Intellectual Property Law & Practice 2008 3(4):210-212; doi:10.1093/jiplp/jpn019
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
3/4/210    most recent
jpn019v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Roche, J.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2008). Published by Oxford University Press. All rights reserved

Current Intelligence

Advanced therapies and the outer limits of DNA regulation: new horizons for patents or a scaffold too far?

Jim Roche
Athlone Institute of Technology, Ireland

EC Regulation 1394/2007 on advanced therapy medicinal products and amending EC Directive 2001/83 and EC Regulation 726/2004

This Regulation seeks to regulate existing and future advanced therapy medicinal products intended for the market in Member States, being either prepared industrially or manufactured by a method involving an industrial process, and introduces additional provisions to those laid down in the pharmaceutical legislation Directive 2001/83.

Correspondence: Email: jroche{at}ait.ie


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.